Clinical Trial DRUG E7777-G000-302
- A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Principal Investigator
- Timothy Kuzel
- Status: SUSPENDED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG E7777-G000-302
- The purpose of this study is to evaluate the effects, good and/or bad, of the drug E7777 in the treatment of persistent (continuous) or recurrent (disease keeps coming back) cutaneous T-cell lymphoma (CTCL).
- CTCL is a rare form of skin cancer. When CTCL is persistent or recurrent the medical and scientific community is always looking for new treatments that may have success with controlling this cancer. E7777 is an investigational drug (it has not been approved by the Food and Drug Administration). There is not yet evidence of the benefits of E7777.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have confirmed CTCL (mycosis fungoides [MF] or Sezary Syndrome [SS]).
- Participants must have had prior therapy for CTCL.
- Description of Treatment
- This study has two parts. The first part (the Lead-In part) will evaluate different doses of E7777. The second part (the Main Study) will assess E7777’s ability to control CTCL and will start after the end of the Lead-In part of the study. Participants in the Lead-In part of the study will receive the study drug by intravenous (IV through a vein) for 5 straight days every 3 weeks. Each 3 week period is called a cycle. Participants may continue up to 8 cycles (24 weeks) of treatment at most or be taken off treatment before that if their disease worsens or the study doctor thinks it is in their best interest to stop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Timothy Kuzel
- Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
- Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
- A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
- A Phase Ib/II Trial of ALT-801 in Combination with Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
- A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone
- A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
- A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
- A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas
- Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma
- A Randomized Phase II Study of Sequential Biotherapy with Aflibercept and High Dose IL-2 versus High Dose IL-2 alone in Patients with Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
- A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma
- Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma (GU10-147)
- A Phase 1/2 study combining Ipilimumab with Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-Naïve Patients with Progressive Metastatic Castration-Resistant Prostate Cancer
last updated: 21-Dec-14 11:37 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.